Dexycu

The primary endpoint was the proportion of patients with complete AC cell clearing (cell score=0) on postoperative day 8. Study protocol allowed for use of rescue medication only when the prespecified rescue criteria were met for AC cell grade 3 and/or AC flare grade 3 at a follow-up visit after surgery.1,2 With a single injection at the end of cat... aract surgery, anti-inflammatory efficacy begins as early as day 1 and continues through day 301 DEXYCU® (dexamethasone intraocular suspension) 9% is indicated for the treatment of postoperative inflammation. Prolonged use of corticosteroids, including DEXYCU, may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of corticosteroids The use of DEXYCU, as with other ophthalmic corticosteroids, is not recommended in the presence of most active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal disease of ocular structures Fungal infections of the cornea are particularly prone to coincidentally develop with long-term local steroid application and must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infectionRead More